Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran 15459-13487, Iran.
Australasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton, VIC 3168, Australia.
Photodiagnosis Photodyn Ther. 2023 Jun;42:103614. doi: 10.1016/j.pdpdt.2023.103614. Epub 2023 May 16.
The future of molecular-level therapy, efficient medical diagnosis, and drug delivery relies on the effective theragnostic function which can be achieved by the synergistic effect of fluorescent carbon dots (FCDs) liposomes (L) and nanoliposomes. FCDs act as the excipient navigation agent while liposomes play the role of the problem-solving agent, thus the term "theragnostic" would describe the effect of LFCDs properly. Liposomes and FCDs share some excellent at-tributes such as being nontoxic and biodegradable and they can represent a potent delivery system for pharmaceutical compounds. They enhance the therapeutic efficacy of drugs via stabilizing the encapsulated material by circumventing barriers to cellular and tissue uptake. These agents facilitate long-term drug biodistribution to the intended locations of action while eliminating systemic side effects. This manuscript reviews recent progress with liposomes, nanoliposomes (collectively known as lipid vesicles) and fluorescent carbon dots, by exploring their key characteristics, applications, characterization, performance, and challenges. An extensive and intensive understanding of the synergistic interaction between liposomes and FCDs sets out a new research pathway to an efficient and theragnostic / theranostic drug delivery and targeting diseases such as cancer.
荧光碳点（FCDs）脂质体（L）和纳米脂质体的协同作用能够实现分子水平治疗、高效医学诊断和药物输送的未来，而这依赖于有效的治疗诊断功能。FCDs 作为赋形导航剂，脂质体则作为解决问题的试剂，因此术语“治疗诊断”可以恰当地描述 LFCD 的作用。脂质体和 FCDs 具有一些优良的特性，如无毒、可生物降解，并且可以作为药物化合物的有效输送系统。它们通过绕过细胞和组织摄取的障碍来稳定包封材料，从而提高药物的治疗效果。这些试剂有助于将药物在体内的长期生物分布到预期的作用部位，同时消除全身副作用。本文通过探索脂质体、纳米脂质体（统称为脂质体）和荧光碳点的关键特性、应用、表征、性能和挑战，综述了它们的最新进展。对脂质体和 FCD 之间的协同相互作用的深入了解，为高效治疗诊断/治疗药物输送和靶向癌症等疾病开辟了一条新的研究途径。
